SEC Foi	rm 4 FORM	4	UNITE) STA	TES S	ECURITIE	ES /	ANI	DE	ХСНА	NO	GE CC	оммі	SSIC	DN					
			Washington, D.C. 20549												OMB APPROVAL					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											Estima	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5					
1. Name and Address of Reporting Person [*] Jerel Davis						2. Issuer Name and Ticker or Trading Symbol <u>Turnstone Biologics Corp.</u> [TSBX]									ship of applica irector	,	g Perso X	wner		
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 10/16/2023								Officer (give title Other (specify below) below)					specify	
C/O TURNSTONE BIOLOGICS CORP. 9310 ATHENA CIRCLE, SUITE 300					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indivi Line) X								e)						
(Street)															Form filed by More than One Reporting Person					
LA JOL	LA C	A	92037		Rule	Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	ole I - Nor	n-Deriv	ative Se	ecurities Ac	quir	red,	Disp	osed (of, c	or Bene	eficial	y Ow	ned					
1. Title of Security (Instr. 3) 2. Transau Date (Month/Date)						2A. Deemed Execution Date, if any (Month/Day/Yea	, Τι C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)						ly	Form:	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									v	Amount		(A) or (D)	Price	Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
		-				curities Acq Is, warrants								Own	ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, T				Expi	6. Date Exercisable and Expiration Date (Month/Day/Year)			of Un De	Title and A Securities Iderlying Privative S str. 3 and	ecurity	Derivative derivat Security Securit (Instr. 5) Benefic Owned Followi Report		9. Number derivative Securities Beneficial Owned Following Reported Transactio	i Iy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)	

	Security				(A) or Disposed of (D) (Instr. 3, 4 and 5)							Following Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)	
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.61	10/16/2023	A		25,540		(1)	10/15/2033	Common Stock	25,540	\$0.00	25,540	D	

Explanation of Responses:

1. Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the date of the first annual general meeting of stockholders occurring after October 12, 2023, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

<u>/s/ P. Joseph Campisi, Jr.,</u> <u>Attorney-in-Fact</u>

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date

10/17/2023